PREGNANCY OUTCOMES IN PATIENTS EXPOSED TO VOCLOSPORIN: A SUMMARY OF AVAILABLE DATA FROM CLINICAL TRIALS AND POST-MARKETING SOURCES (EULAR 2025) - May 29, 2025 - Abstract #ABS0383; P2, P3 | "Therapeutic agents including mycophenolate mofetil (MMF), commonly used in LN, have also been linked to birth defects and pregnancy loss. Active LN in pregnancy is associated with an increased risk of adverse maternal and fetal outcomes, and observations from this limited cohort reflect the overall challenges faced by female patients of child-bearing age with active LN. The limited data presented here are insufficient to draw conclusions regarding the use of voclosporin during pregnancy, and additional research is needed to better characterize maternal and fetal outcomes following voclosporin exposure."
Clinical • P4 data • Cardiovascular • Dermatology • Glomerulonephritis • Gynecology • Hypertension • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Ocular Inflammation • Ophthalmology • Psoriasis • Systemic Lupus Erythematosus • Uveitis
|
|
E. Y. Chock 1; T. Begum 2; K. Dao 2; C. Zhou 2; M. Dardeno 2
|